Recruiting Rheumatoid Arthritis Studies in Hagerstown
A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
The goal of this clinical trial is to learn if MELT-300 works on procedural sedation in adult participants undergoing cataract extraction with lens replacement (CELR). It will also learn about the saf...
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
This Phase 3, multicenter, double-masked, parallel-group, placebo-controlled, randomized, fixed-dose clinical study is designed to evaluate the efficacy and safety of tinlarebant (LBS-008) in subjects...
Single Intravitreal Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration...
A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD
Age-related macular degeneration (AMD) affects millions of elderly patients. When advanced, there is Geographic Atrophy (GA) in the retina. This means that there is an area with a loss of light-sensit...
A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration
EYE-TIE-201 is a 2-part study to investigate the safety and effectiveness of a new drug being developed called EYE201. All participants in the study will receive a total of 3 injections of EYE201 int...
About Rheumatoid Arthritis Clinical Trials in Hagerstown
Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting approximately 1.3 million Americans, where the immune system mistakenly attacks joint linings, causing painful swelling, bone erosion, and joint deformity. Early diagnosis and treatment are critical to prevent irreversible damage. Current standard treatments include methotrexate and other DMARDs, TNF inhibitors (etanercept, infliximab), IL-6 inhibitors (tocilizumab), T-cell costimulation modulators (abatacept), and JAK inhibitors (tofacitinib, baricitinib). Clinical trials are now exploring next-generation targeted therapies, dual-pathway inhibitors, and treatment strategies aimed at achieving sustained remission rather than just symptom control. Patients with inadequate response to conventional DMARDs or biologics are commonly eligible for enrollment.
There are currently 5 rheumatoid arthritis clinical trials recruiting participants in Hagerstown, MARYLAND. These studies are seeking a combined 1,559 participants. Research is being sponsored by Melt Pharmaceuticals, Belite Bio, Inc, 4D Molecular Therapeutics and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Rheumatoid Arthritis Clinical Trials in Hagerstown — FAQ
Are there rheumatoid arthritis clinical trials in Hagerstown?
Yes, there are 5 rheumatoid arthritis clinical trials currently recruiting in Hagerstown, MARYLAND. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Hagerstown?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Hagerstown research site will contact you about next steps.
Are clinical trials in Hagerstown free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Hagerstown studies also compensate for your time and travel.
What rheumatoid arthritis treatments are being tested?
The 5 active trials in Hagerstown are testing new therapies including novel drugs, biologics, and treatment approaches for rheumatoid arthritis.
Data updated March 2, 2026 from ClinicalTrials.gov